UroGen Pharma Ltd. URGN R2K

Healthcare · Biotechnology · United States

https://www.urogen.com

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Market & Price

Market Cap

$1.37B

Current Price

$28.13

High / Low (52W)

$31.33 / $4.24

Beta

1.59

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

22.89

PEG Ratio

Book Value

$-2.55

Price to Book

-11.03

P/S

9.76

EV/EBITDA

-13.23

Dividend Yield

Profitability & Returns

ROCE

-89.63%

ROE

ROA

-26.98%

Profit Margin

-94.83%

Op Margin

-39.76%

EPS (Latest Qtr)

$-0.47

EPS (TTM)

$-2.74

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

3.87

Current Ratio

4.69

Debt

$197.09M

Total Assets

$200.46M

Current Assets

$186.02M

Working Capital

$139.61M

Ownership

Promoter Holding

3.65%

Chg in Prom Hold

FII / Inst Holding

99.43%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.43B

Total Revenue (TTM)

$140.49M

EBITDA

$-107.90M

Free Cash Flow

$-109.28M

Operating Cash Flow

$-165.74M

Shares Outstanding

48.72M

Gross Margin

89.85%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

19.49%

Profit 5Y

-13.27%

Revenue (YoY)

151.60%

Earnings (YoY)

PROS

Compounding revenue at 19.5% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -13.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	URGN UroGen Pharma Ltd. R2K	28.13	-	$1.37B	-	-89.63%	-	19.49%	-13.27%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	481.00K	364.00K	283.00K	-	-	18.00K	-	-	-	372.00K	3.46M	7.49M	13.03M	11.35M	13.56M	16.60M	16.10M	17.19M	21.14M	20.85M	23.53M	18.78M	21.85M	-	-	20.25M	24.21M	27.48M	37.84M	50.96M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.33M	3.55M	3.28M	3.29M	4.14M
Gross Profit	-	-	-	-	51.00K	46.00K	-772.00K	-	-	18.00K	-	-	-	324.00K	3.15M	6.59M	11.61M	10.11M	12.04M	14.76M	14.08M	14.93M	18.70M	18.48M	21.24M	17.05M	19.62M	-	-	17.92M	20.66M	24.20M	34.55M	46.82M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54.84M	62.11M	51.59M	53.66M	67.08M
Operating Income	-3.54M	-5.95M	-303.00K	-10.16M	-13.64M	-18.43M	-21.09M	-24.02M	-22.43M	-23.75M	-23.45M	-39.84M	-38.56M	-31.80M	-29.12M	-26.11M	-22.82M	-23.44M	-21.96M	-18.71M	-18.09M	-22.05M	-15.38M	-13.50M	-	-25.74M	-25.84M	-	-	-36.91M	-41.45M	-27.39M	-19.11M	-20.26M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38.89M	-44.20M	-30.39M	-22.19M	-23.51M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.07M	4.13M	3.37M	3.77M	4.18M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-43.45M	-48.92M	-34.40M	-26.64M	-28.35M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	392.00K	1.01M	-1.05M	-275.00K	-4.77M
Net Income	-3.42M	-6.20M	-298.00K	-10.09M	-13.38M	-18.03M	-20.53M	-23.72M	-21.44M	-22.48M	-22.25M	-38.97M	-37.79M	-31.35M	-28.82M	-25.93M	-26.22M	-30.21M	-28.39M	-26.69M	-25.83M	-30.21M	-24.14M	-21.88M	-26.02M	-32.29M	-33.40M	-	-	-43.84M	-49.94M	-33.35M	-26.36M	-23.57M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.92	-1.05	-0.69	-0.54	-0.47
R&D Expense	-	-	-	-	-	8.27M	9.57M	-	9.73M	10.00M	9.48M	-	16.59M	8.11M	10.21M	10.51M	12.12M	11.92M	12.70M	12.64M	13.09M	12.50M	11.58M	10.23M	-	15.49M	15.40M	11.36M	-	19.87M	18.91M	14.01M	-	15.60M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	8.16M	1.13M	18.00K	11.80M	-	64.36M	82.71M	90.40M	109.79M
Cost of Revenue	-	-	-	-	-	-	7.65M	9.36M	8.88M	12.45M
Gross Profit	17.50M	7.56M	-675.00K	18.00K	10.79M	-	56.70M	73.35M	81.52M	97.34M
Operating Expenses	-	-	-	-	-	-	135.74M	138.89M	178.30M	222.20M
Operating Income	798.00K	-19.95M	-77.18M	-109.48M	-126.74M	-	-79.04M	-65.54M	-96.78M	-124.86M
EBITDA	-	-	-	-	-	-	-97.77M	-81.90M	-110.33M	-135.66M
Interest Expense	-	-	-	-	-	-	8.44M	14.71M	12.52M	15.35M
Pretax Income	-	-	-	-	-	-	-108.03M	-98.32M	-124.04M	-153.42M
Tax Provision	-	-	-	-	-	-	1.75M	3.92M	2.83M	78.00K
Net Income	-1.94M	-20.00M	-75.66M	-105.15M	-128.48M	-	-109.78M	-102.24M	-126.87M	-153.49M
Diluted EPS	-	-	-	-	-	-	-4.79	-3.55	-2.96	-3.19
R&D Expense	-	18.70M	36.93M	49.30M	47.31M	47.64M	52.91M	45.61M	57.15M	67.11M

Compounded Sales Growth

5 Years:	19.49%
1 Year:	151.60%

Compounded Profit Growth

5 Years:	-13.27%
1 Year:	-

Stock Price Performance

1 Year:	+563.44%
6 Months:	+1.59%
3 Months:	+29.63%
1 Month:	+20.52%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	75.55M	103.56M	202.39M	122.00M	-	135.62M	178.31M	285.71M	200.46M
Current Assets	-	-	-	-	-	-	-	128.91M	169.19M	276.13M	186.02M
Cash & Equivalents	-	-	37.00M	101.32M	49.69M	52.86M	-	55.41M	95.00M	171.99M	110.75M
Inventory	-	-	-	-	-	-	-	4.33M	5.67M	9.23M	16.46M
Receivables	-	-	-	-	-	-	-	12.70M	15.44M	20.30M	33.08M
Total Liabilities	-	-	7.04M	13.46M	22.09M	25.65M	-	224.98M	243.52M	294.51M	305.93M
Current Liabilities	-	-	7.04M	13.46M	19.48M	21.44M	-	23.92M	31.21M	45.95M	46.42M
Long Term Debt	-	-	-	-	-	-	-	97.54M	98.55M	121.73M	122.21M
Total Debt	-	-	-	-	-	-	-	99.12M	99.39M	123.39M	128.33M
Total Equity	16.28M	16.31M	68.52M	90.09M	180.30M	96.36M	-	-89.36M	-65.21M	-8.80M	-105.47M
Shares Outstanding	-	-	-	-	-	-	-	23.13M	32.49M	42.23M	48.35M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	4.19M	-9.57M	-37.33M	-71.02M	-105.89M	-	-87.56M	-76.38M	-96.77M	-162.44M
Investing Cash Flow	-719.00K	-36.28M	35.29M	-145.59M	93.24M	-	1.06M	-953.00K	-20.61M	61.56M
Financing Cash Flow	-9.00K	61.59M	66.42M	165.25M	16.53M	-	97.13M	116.93M	194.62M	39.92M
Capital Expenditure	-695.00K	-271.00K	-560.00K	-325.00K	-1.22M	-	-254.00K	-194.00K	-295.00K	-289.00K
Free Cash Flow	3.49M	-9.84M	-37.89M	-71.34M	-107.10M	-	-87.81M	-76.57M	-97.06M	-162.73M
Net Change in Cash	-	-	-	-	-	-	10.63M	39.60M	77.24M	-60.97M

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	92.6%	-59.8%	100.0%	91.4%	-	88.1%	88.7%	90.2%	88.7%
Operating Margin %	-	-244.5%	-6,842.2%	-608,211.1%	-1,074.2%	-	-122.8%	-79.2%	-107.1%	-113.7%
Net Margin %	-	-245.2%	-6,707.2%	-584,144.4%	-1,088.9%	-	-170.6%	-123.6%	-140.4%	-139.8%
ROE %	-11.9%	-29.2%	-84.0%	-58.3%	-133.3%	-	122.9%	156.8%	1,441.3%	145.5%
ROCE %	-	-29.1%	-85.7%	-59.9%	-126.0%	-	-70.8%	-44.6%	-40.4%	-81.1%

Shareholding Pattern

Insiders

3.65%

Institutions

99.43%

Public Float

103.19%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	RTW Investments LP	9.33%	4.54M	$127.82M
2	Blackrock Inc.	5.84%	2.85M	$80.05M
3	Toronto Dominion Bank	5.37%	2.62M	$73.61M
4	Morgan Stanley	5.25%	2.56M	$72.01M
5	Kynam Capital Management, LP	4.61%	2.25M	$63.22M
6	Jefferies Financial Group Inc.	4.51%	2.20M	$61.88M
7	Paradigm Biocapital Advisors LP	3.50%	1.70M	$47.93M
8	Acorn Capital Advisors, LLC	3.43%	1.67M	$47.07M
9	SG Americas Securities, LLC	3.40%	1.66M	$46.64M
10	American Century Companies Inc	3.36%	1.64M	$46.06M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for URGN

No recent headlines available.

URGN · Healthcare